𝔖 Bobbio Scriptorium
✦   LIBER   ✦

2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders

✍ Scribed by D. Rondelli; F. Lauria; P. L. Zinzani; D. Raspadori; M. A. Ventura; P. Galieni; S. Birtolo; F. Forconi; R. Algeri; S. Tura

Book ID
114792297
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
481 KB
Volume
58
Category
Article
ISSN
0902-4441

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

2-chlorodeoxyadenosine (2-CDA) for the t
2-chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients
✍ Stine, Kimo C.; Saylors, Robert L.; Williams, Laura L.; Becton, David L. πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 192 KB πŸ‘ 2 views

Background. Pediatric patients with Langerhans cell histiocytosis (LCH) may become refractory to conventional therapy or present with repeated recurrences over several years. Current therapeutic options such as prednisone, vinblastine, etoposide, and cyclosporine are associated with significant acut

Mitoxantrone in the treatment of relapse
Mitoxantrone in the treatment of relapsed and refractory acute leukemia
✍ P. Meyer; A. D. Ho; G. Ehninger; I. Mjaaland; E. Heidemann; E. Seither πŸ“‚ Article πŸ“… 1985 πŸ› Springer US 🌐 English βš– 245 KB

Twenty-four patients with acute leukemia or blast crisis (BC) of chronic myelocytic leukemia (CML) in relapse or refractory to standard chemotherapy, were eligible for treatment with mitoxantrone. Mitoxantrone (Novantrone| dihydroxyanthracenedione) was administered in a dose of 8-13 mg/m 2 on five c